Navigation Links
Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier
Date:7/31/2009

SHENZHEN, China, July 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced today that its registration dossier for MEVAC-DTaP (Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed) had passed the preliminary consideration of the experts in Thai FDA. The sample analysis is expected to be completed within the next 30 days.

Mr. Terry Yuan CEO of HTDS said (sic) "We welcome the expanded role of the medical team in Serbia. There has been a great synergy between the medical group in Serbia and us here in China, right from day one. I have great admiration for the work they are doing which is simply amazing. It is our goal and target to see the fruits of our labour begin to pay off for us and all of our shareholders.

HTDS was a company acquired by the new management, with the backing of our financiers' under duress, just less than a year ago. Many of HTDS long time shareholders basically witnessed HTDS share values dwindle down to next to nothing. Our goal is to reverse that trend and we believe we are well under way. We have received a number of inquiries about an open Regulation D financing and filing we did. HTDS is a medical company engaged in both RD and vaccine distribution as its core business. Over the next several weeks and months we will be issuing many updates as to what progress the company made. By that we mean, how this financing was used, what equipment was acquired, contracts signed and what assets were acquired, and more importantly the forward strides we made as a company. Our days of being under duress and in peril are well behind us now.

Today, in less than a year we have two very vibrant companies in HTDS. We are focused, determined and the two companies are working hard and there is great synergy and sync between us all. The Mellow Hope division generates revenues and steady cash flows that a business is judged upon, and generally valuated. Slavica Bio Chem on the other hand is a company whose research and development can have astronomical growth impact on our whole organization, and our share price, which by all accounts I can safely say continues to be very undervalued"

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cancer Survivors Face Tough Road Long After Treatment Ends
2. Judge Sues Blue Cross for Autism Treatment
3. FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
4. Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment
5. New Spanish-Language Consumer Guides Compare Treatments for Depression, Prostate Cancer and Other Conditions
6. Alternative Therapies for Fighting Eczema Hold Promise, But Dermatologists Caution They Are No Substitute for Proven Medical Treatments
7. New Laser Treatment for Cellulite Helps Fight the Battle
8. New BioTrends Report Explores Anticipated Treatment Pattern Shifts Expected with the Proposed Bundled Payment Structure Planned for 2011
9. NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
10. New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants
11. Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology: